{"id":293258,"date":"2024-06-17T00:00:00","date_gmt":"2024-06-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0010-2024-biopharma-schizophrenia-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-05-05T23:17:36","modified_gmt":"2026-05-05T23:17:36","slug":"cutrcg0010-2024-biopharma-schizophrenia-current-treatment-current-treatment-physician-insights-schizophrenia-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0010-2024-biopharma-schizophrenia-current-treatment-current-treatment-physician-insights-schizophrenia-us\/","title":{"rendered":"Schizophrenia &#8211; Current Treatment &#8211; Current Treatment: Physician Insights \u2013 Schizophrenia (US)"},"content":{"rendered":"<p>In the United States, atypical antipsychotics available in oral and injectable (e.g., long-acting injectable [<abbr title=\"long-acting injectable\">LAI<\/abbr>]) formulations are the mainstay of schizophrenia treatment. However, the dearth of effective therapies to treat the negative symptoms and cognitive impairment associated with the disease leaves substantial unmet need. Given the availability of newer, more-tolerable oral atypical antipsychotics (e.g., Intra-Cellular Therapies\u2019 Caplyta) and newer <abbr title=\"long-acting injectable\">LAI<\/abbr>s offering dosing flexibility among other advantages (e.g., Otsuka\/Lundbeck\u2019s Abilify Asimtufii), the clinical heterogeneity of schizophrenia, and patients\u2019 varied responses to antipsychotic therapy, the treatment landscape is undergoing conspicuous changes. Multiple factors such as tolerability, compliance, market access, clinical profile, route, and frequency of administration appeal differentially to patients and psychiatrists alike when making treatment choices. Understanding the prescribing patterns in this space and the challenges that psychiatrists face treating this disease is indispensable for marketers of current branded therapies (e.g., AbbVie\u2019s Vraylar, Johnson &#038; Johnson Innovative Medicine\u2019s Invega Trinza, Otsuka\/Lundbeck\u2019s Abilify Maintena) and for developers of emerging therapies.<\/p>\n<ul class=\"round-bullets\">\n<li>What percentage of schizophrenia patients are on antipsychotic treatment, and what is the patient share of individual therapies?<\/li>\n<li>How are patients treated in different lines of therapy, and what drives the switching to specific brands?<\/li>\n<li>When and why do psychiatrists introduce antipsychotic <abbr title=\"long-acting injectable\">LAI<\/abbr>s into their patients\u2019 treatment?<\/li>\n<li>What percentage of patients present with negative symptoms and\/or cognitive impairment, and how are they treated?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Current Treatment: Physician Insights<\/em> provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Geography:<\/strong> United States.<\/p>\n<p><strong>Primary Research<\/strong>: Survey of 101 U.S. psychiatrists<\/p>\n<p><strong>Key companies:<\/strong> AbbVie, Alkermes, Johnson &#038; Johnson Innovative Medicine, Indivior, Intra-Cellular Therapies, Lundbeck, Otsuka, Sumitomo Pharma \/ Sunovion Pharmaceuticals, Teva, Luye Pharma<\/p>\n<p><strong>Key drugs covered: <\/strong>Abilify Maintena, Abilify Asimtufii, Invega Hafyera, Aristada, Invega Sustenna, Invega Trinza, Rexulti, Uzedy, olanzapine, clozapine, Vraylar, Caplyta, Lybalvi, Rykindo<\/p>\n<p><strong>Key insights provided<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Factors influencing disease management and treatment decisions<\/li>\n<li>Drivers and constraints of treatment selection<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares<\/li>\n<li>Rationale for changes in treatment approach<\/li>\n<li>Physician insight on persistency and compliance<\/li>\n<li>Physician-reported recent \/ anticipated changes in brand usage or treatment approach<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-293258","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psychiatry","biopharma-therapy-areas-schizophrenia","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293258\/revisions"}],"predecessor-version":[{"id":575948,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293258\/revisions\/575948"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=293258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}